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Myocardial scintigraphy using a fatty acid analogue detects
coronary artery disease in hemodialysis patients.
Background. Coronary artery disease contributes signifi-
cantly to mortality in end-stage renal disease (ESRD) pa-
tients. Single-photon emission computed tomography (SPECT)
using an iodinated fatty acid analogue, iodine-123-methyl
iodophenylpentadecanoic acid (123I-BMIPP), can assess fatty
acid metabolism in the myocardium. We investigated the abil-
ity of 123I-BMIPP SPECT to detect coronary artery disease
in hemodialysis patients compared with 201thallium chloride
(201Tl) SPECT.
Methods. We prospectively studied 130 ESRD patients un-
dergoing hemodialysis for a mean of 88.6 months (male/female,
77/53; mean age, 63.8 years). Dual SPECT using 123I-BMIPP
and 201Tl was performed, followed by coronary angiography.
SPECT findings were graded in 17 segments on a five-point
scale (0, normal uptake; 4, none) and assessed as a summed
score.
Results. By coronary angiography, 71.5% of patients (93/130)
had significant coronary stenosis (≥75%), and five patients
showed coronary spasm without coronary stenosis. When a
BMIPP summed score of 6 or more was defined as abnor-
mal, sensitivity, specificity, and accuracy for detecting coro-
nary artery disease by BMIPP SPECT were 98.0%, 65.6%, and
90.0%, respectively; in contrast, these parameters for detecting
coronary artery disease by Tl SPECT were 84.7%, 46.9%, and
75.0%, respectively, when a Tl summed score of 1 or more was
defined as abnormal. In receiver operating characteristic anal-
ysis, the area under the curve was 0.895 in BMIPP and 0.727 in
Tl SPECT, respectively.
Conclusion. Resting BMIPP SPECT is superior to Tl SPECT
for detecting coronary lesions, and provides safe screening
for coronary artery disease among maintenance hemodialysis
patients.
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Cardiovascular disease is the single best predictor
of mortality in patients with end-stage renal disease
(ESRD) [1, 2]. Postmortem and coronary angiographic
studies have shown that ischemic heart disease from
stenosis of coronary arteries is very common in ESRD
patients. Prevalence of coronary artery stenosis in ESRD
patients varies from 24% in young nondiabetic hemodial-
ysis patients [3] to 85% in elderly diabetic uremic patients
[4]. Seventy-three percent of hemodialysis patients were
reported to have more than 50% stenosis in one coro-
nary artery [5]. Another study of 67 hemodialysis patients
found that 23% of hemodialysis patients demonstrated
evidence of silent myocardial ischemia according to am-
bulatory electrocardiographic monitoring carried out for
at least 12 hours [6]. Although the prevalence of coronary
artery disease in the dialysis population depends upon the
definition used, it appears to be much higher in ESRD pa-
tients undergoing hemodialysis than in a non-ESRD pop-
ulation. Coronary angiography, the “gold standard” for
diagnosis of coronary disease, is unsuitable for screening
for coronary artery disease in hemodialysis patients be-
cause vascular complications in coronary artery disease
reportedly are nearly 20 times more likely in hemodial-
ysis than in nonhemodialysis patients [abstract; Hajj-Ali
R, et al, Am J Cardiol 90 (Suppl 6A):168H, 2002]. Effec-
tiveness of combined dipyridamole-exercise 201thallium
chloride (201Tl) scintigraphy, combined dipyridamole-
exercise stress echocardiography, and dobutamine stress
echocardiography in screening for coronary artery dis-
ease has been reported in ESRD patients [7, 8, 9]. In
practice, however, many patients apparently cannot per-
form these stress tests properly. Exercise stress sufficient
to produce evaluable results may be impossible to at-
tain in some cases because exercise tolerance generally
is reduced in hemodialysis patients. Additionally, admin-
istration of drugs that influence cardiovascular function
may elicit extreme changes in blood pressure or heart rate
in hemodialysis patients since their autonomic function
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Table 1. Characteristics of the 130 subjects
Male gender % 77 (59.2%)
Age years 63.8 ± 10.4
Hemodialysis duration months 88.6 ± 89.0
Presence of diabetes mellitus % 61 (46.9%)
Serum hemoglobin A1c concentration (N = 61) % 6.1 ± 1.2
Hematocrit % 32.3 ± 2.8
Serum hemoglobin g/L 105 ± 9
Serum albumin g/L 39.7 ± 4.5
Serum total cholesterol mmol/L 4.1 ± 0.3
Systolic blood pressure before hemodialysis mm Hg 146 ± 16
Diastolic blood pressure before hemodialysis mm Hg 73 ± 11
Systolic blood pressure after hemodialysis mm Hg 132 ± 19
Diastolic blood pressure after hemodialysis mm Hg 64 ± 10
Cardiothoracic ratio % 52.0 ± 5.1
Left ventricular internal end-diastolic dimension mm 50.8 ± 7.3
Left ventricular internal end-systolic dimension mm 34.2 ± 7.9
Left ventricular fractional shortening % 33.3 ± 9.7
Left ventricular ejection fraction % 60.6 ± 13.7
Interventricular septal wall thickness mm 11.7 ± 3.2
Left ventricular posterior wall thickness mm 9.3 ± 2.1
in hemodialysis patients often is impaired. Therefore, a
test is needed that requires neither exercise nor drug
administration to screen for coronary artery disease in
hemodialysis patients. Over 70% of the energy required
by the normal myocardium under aerobic conditions de-
rives from metabolism of free fatty acids (FFA) [10]. Un-
der hypoxic or ischemic conditions, fatty acid metabolism
is believed to be suppressed and replaced by glucose
metabolism, which requires less oxygen consumption
[11]. Iodine-123-methyl iodophenyl-pentadecanoic acid
(123I-BMIPP) is a branched FFA analogue characterized
by resistance to b-oxidation. Recent studies indicate pos-
sible effectiveness of single-photon emission computed
tomography (SPECT) using 123I-BMIPP as a tracer in
diagnosis of organic coronary lesions, unstable angina
pectoris, or coronary spasm without exercise or drugs
[12–22]. In the present study, we investigated whether
123I-BMIPP SPECT could be useful in screening for coro-
nary artery disease in ESRD patients undergoing main-
tenance hemodialysis. This modality was compared with
201Tl SPECT, which has been used for evaluating the coro-
nary circulation.
METHODS
Patients
We prospectively enrolled 130 ESRD patients under-
going maintenance hemodialysis for more than 3 months
at Toujinkai Hospital (77 male and 53 female; mean age,
63.8 ± 10.4 years) (Table 1). Patients diagnosed with
acute or old myocardial infarction, unstable angina pec-
toris, idiopathic hypertrophic or dilated cardiomyopathy,
or congestive heart failure (New York Heart Association
grades III to IV) were excluded. Of 130 subjects, 61 had
diabetes mellitus (46.9%), and 23 of 61 diabetic patients
had been receiving insulin therapy. Blood pressure was
measured hourly during dialysis using a mercury sphyg-
momanometer; for study purposes it was determined as
the mean of the measurements obtained at eight differ-
ent midweek hemodialysis sessions before examination
by myocardial scintigraphy. Hemodialysis was performed
three times weekly using a dialysate containing Na+
(140 mEq/L), K+ (2.0 mEq/L), Cl− (110 mEq/L), Ca2+
(3.0 mEq/L), Mg2+ (1.0 mEq/L), HCO3− (30 mEq/L),
and CH3COO− (10 to 15 mEq/L). Membranes used in
the dialyzer were either cellulose triacetate (FB-190F)
(Nipro, Tokyo, Japan), surface modified regenerated cel-
lulose (AMBC-20X) (Asahi Medical, Tokyo, Japan),
polymethyl methacrylate (FB-2.1F) (Toray Medical,
Tokyo, Japan) or polysulfone (PS-1.9UW) (Kawasumi
Laboratory, Tokyo, Japan). Dialysis filter surface areas
were 1.8 to 2.1 m2. The Ethical Committee for Human
Research of Toujinkai Hospital approved this study, and
all patients provided informed consent for participation.
Radionuclide imaging
All patients underwent resting 123I-BMIPP and 201Tl
scintigraphy under pain-free conditions after fasting for
over 6 hours. Each dose of 111 MBq of 123I-BMIPP
(Nihon Medi-Physics, Tokyo, Japan) and 201Tl (Nihon
Medi-Physics) was injected intravenously with patients
seated. Fifteen minutes after the injection, data for
SPECT were acquired from a 64 × 64 matrix in 32 direc-
tions, at 6◦ intervals from the 45◦ right anterior oblique
position to the 45◦ left posterior oblique position, for
30 seconds per direction, using a commercially available
gamma camera (Starcam 4000i) (GE Medical Systems,
Waukesha, WI, USA) equipped with a low-energy, all-
purpose collimator. The energy discrimination of 123I-
BMIPP was centered at 159 keV with a 20% window,
and that of 201Tl was centered at 90 keV with a 20% win-
dow. Data were entered into an online nuclear medicine
data processor (IMC12C4-5) (GE Medical Systems). To-
mographic images then were constructed with short-axis,
horizontal-axis, and vertical-axis sections. The threshold
level was 20%, and absorption was not corrected. The
ventricular SPECT images were divided into 17 segments
for semiquantative analysis according to the standard my-
ocardial segmentation for tomographic imaging of the
heart established by the American Heart Association
[23]. Radioactivity of each segment was graded visually
and assigned a score from 0 to 4 (0, normal uptake; 1,
mildly reduced; 2, moderately reduced; 3, severely re-
duced; and 4, no uptake). The sum of scores by BMIPP
or Tl SPECT, including 17 myocardial segments, was des-
ignated the BMIPP summed score or the Tl summed
score. The same experienced technician performed scinti-
graphic procedures in all cases, and the same two investi-
gators who had no clinical information about the patients
interpreted the images in all cases.
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Coronary angiography
All patients underwent coronary angiography within
60 days of BMIPP-Tl dual SPECT in the Department
of Interventional Cardiology of the Second Kyoto Red
Cross Hospital. Stenoses of coronary vessels were coded
according to the criteria of the American Heart Associa-
tion reporting system. Luminal stenoses with 75%, 90%,
99%, or 100% occlusion were defined as significant le-
sions, while patients with luminal stenoses of 50% or less
were included in the normal coronary group.
Echocardiographic measurements
A two-dimensionally guided M-mode echocardiogram
was obtained for each patient using a single ultrasono-
graphic recorder (UF-8800) (Fukuda Denshi, Tokyo,
Japan) on a midweek nondialysis day in the week follow-
ing BMIPP-Tl dual SPECT. Left ventricular dimensions
and left ventricular systolic functions such as percent of
left ventricular fractional shortening and left ventricular
ejection fraction were measured and calculated.
Biochemical and hematologic determinations
Blood samples (5 mL) were obtained just before initi-
ation of the hemodialysis following the SPECT examina-
tion, after the patient had been in the supine position for
at least 10 minutes. Hematocrit and serum hemoglobin
were determined as the mean from four different mea-
surements within a 2-month period, which included the
day of the SPECT examination. Serum concentrations
of albumin and total cholesterol were determined as the
mean from four different measurements within a 4-month
period.
Statistical analysis
Data are expressed as the mean ± SD, and differences
between groups were evaluated by one-way analysis of
variance (ANOVA), followed by application of Duncan’s
new multiple-range test. A value of P < 0.05 was consid-
ered to indicate statistical significance.
RESULTS
Coronary angiography findings
Table 2 summarizes the coronary angiography results
in all patients enrolled in this study. Significant coronary
stenoses of 75% or more were found in 93 of 130 pa-
tients (71.5%); six of these 93 patients had stenosis of
the left main trunk. Existence of coronary spasm was as-
certained by an ergonovine test in five patients without
significant coronary stenosis. Of the 98 patients who had
coronary artery disease, including those with coronary
spasm, 79 had not noted chest pain or discomfort (80.6%).
Prevalences of silent myocardial ischemia were 80.0% in
Table 2. Results of coronary angiography
Coronary stenosis of 75% or greater 93/130 (71.5%)
Right coronary artery 51/130 (39.2%)
Left anterior descending artery 61/130 (46.9%)
Left circumflex artery 52/130 (40.0%)
Left main trunk 6/130 (4.6%)
Single-vessel disease 41/130 (31.5%)
Double-vessel disease 28/130 (21.5%)
Triple-vessel disease 18/130 (13.8%)
Left main trunk 6/130 (4.6%)
Coronary spasm 5/130 (3.8%)
diabetic patients (40/50) and 81.3% (39/48) in nondia-
betic patients. Of 93 patients with coronary artery steno-
sis, percutaneous coronary intervention was performed
in 63, and coronary artery bypass grafting was carried
out in nine. Age, Tl summed score, and BMIPP summed
score were higher in patients with coronary artery disease
than in those without (Table 3). Gender, dialysis duration,
presence of diabetes mellitus, hematocrit, serum concen-
trations of hemoglobin, albumin, total cholesterol, blood
pressure, cardiothoracic ratio, and echocardiographic pa-
rameters such as left ventricular dimensions, left ventricu-
lar systolic function, or left ventricular wall thickness did
not differ between patients with and without coronary
artery disease.
In nondiabetic patients, significant coronary steno-
sis was found in 44/69 patients (63.8%) as follows:
right coronary artery, 27/44 (61.4%); left anterior de-
scending, 25/44 (56.8%); left circumflex, 23/44 (52.3%);
and left main trunk, 2/44 (4.5%). Single-vessel disease
was present in 21/44 (47.7%); double-vessel disease,
12/44 (27.3%); and triple-vessel disease, 9/44 (20.5%). In
diabetic patients, significant coronary stenosis was rec-
ognized in 49/61 patients (80.3%) as follows: right coro-
nary artery, 24/49 (49.0%); left anterior descending, 36/49
(73.5%); left circumflex, 29/49 (59.2%); and left main
trunk, 4/49 (8.2%). Single-vessel disease was present in
20/49 (40.8%); double-vessel disease, 16/49 (32.7%); and
triple-vessel disease, 9/49 (18.4%). The prevalence of left
anterior descending lesions was higher in diabetic than in
nondiabetic patients (P < 0.01).
SPECT summed score and coronary stenosis
Figures 1 and 2 show three illustrative cases with signif-
icant coronary stenosis and differences in SPECT imag-
ing between BMIPP and Tl. The mean BMIPP summed
score was higher in patients with 75% coronary stenosis
(16.74 ± 7.41, N = 19) or 90% or greater coronary steno-
sis (22.39 ± 10.42, N = 74) than in those with normal
coronary arteries (6.19 ± 9.07, N = 32). In contrast, the
mean Tl summed score was higher in patients with 90%
or greater coronary stenosis (9.12 ± 6.99, N = 74) than in
those with 75% coronary stenosis (4.26 ± 4.48, N = 19)
or normal coronary arteries (2.59 ± 3.08, N = 32), but did
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Table 3. Differences in clinical and single photon emission computed
tomography (SPECT) variables between patients with or without
coronary artery disease (CAD)
CAD(+) CAD(−)
(N = 98) (N = 32) P value
Male gender % 61 (62.2%) 16 (50.0%) 0.301
Age years 65.2 ± 9.3 59.6 ± 12.4 0.008
Hemodialysis duration months 85.7 ± 82.5 96.9 ± 107.5 0.540
Presence of diabetes mellitus % 50 (51.0%) 11 (34.4%) 0.109
Serum hemoglobin A1c 6.1 ± 1.1 5.9 ± 1.3 0.677
concentration %
Systolic blood pressure before 146 ± 16 145 ± 17 0.670
hemodialysis mm Hg
Diastolic blood pressure before 73 ± 12 76 ± 10 0.166
hemodialysis mm Hg
Systolic blood pressure after 133 ± 18 128 ± 20 0.134
hemodialysis mm Hg
Diastolic blood pressure after 63 ± 10 65 ± 9 0.361
hemodialysis mm Hg
Cardiothoracic ratio % 52.3 ± 5.0 51.1 ± 5.2 0.228
Hematocrit % 32.2 ± 2.9 32.4 ± 3.2 0.869
Serum hemoglobin g/L 105 ± 8 104 ± 9 0.553
Serum albumin g/L 39.5 ± 3.7 40.1 ± 4.8 0.462
Serum total cholesterol mmol/L 4.1 ± 0.4 4.0 ± 0.3 0.286
LVIDd mm 51.2 ± 7.3 49.5 ± 7.1 0.228
LVIDs mm 34.8 ± 8.4 32.5 ± 5.7 0.154
LVFS % 32.7 ± 9.9 35.1 ± 8.8 0.216
LVEF % 59.7 ± 14.4 63.2 ± 11.0 0.200
IVST mm 11.8 ± 3.4 11.6 ± 2.7 0.817
PWT mm 9.3 ± 2.2 9.5 ± 1.7 0.646
T1 summed score 7.9 ± 6.8 2.6 ± 3.1 <0.001
BMIPP summed score 21.2 ± 10.0 6.2 ± 9.1 <0.001
Coronary artery disease included both coronary artery stenosis and spasm.
Abbreviations are: LVIDd, left ventricular internal end-diastolic dimension;
LVIDs, left ventricular internal end-systolic dimension; LVFS, left ventricular
fractional shortening; LVEF, left ventricular ejection fraction; IVST, interven-
tricular septal wall thickness; PWT, left ventricular posterior wall thickness.
not differ between the 75% coronary stenosis and the nor-
mal coronary groups (Fig. 3). In BMIPP and Tl SPECT,
the mean summed score was higher in patients with 90%
or greater coronary stenosis than in those with normal
coronary arteries, irrespective of whether this stenosis in-
volved the right coronary artery, left anterior descending,
or left circumflex. In BMIPP SPECT, the mean summed
score of patients with 75% stenosis was higher when this
stenosis involved the left anterior descending, and tended
to be higher when the right coronary artery was involved,
than the mean summed score of the normal coronary
group. In contrast, the mean summed score in Tl SPECT
did not differ between the 75% coronary stenosis and
normal coronary groups irrespective of which coronary
artery was involved.
SPECT summed score and number of coronary
vessels with significant stenosis
The mean BMIPP summed score was higher in patients
with single-vessel (19.34 ± 10.07, N = 41), double-vessel
(20.75 ± 9.59, N = 28), or triple-vessel coronary disease
(23.11 ± 10.19, N = 18) or in the left main trunk stenosis
group (30.83 ± 8.13, N = 6), than in the normal coro-
nary group (6.19 ± 9.07, N = 32). On the other hand,
the mean Tl summed score was higher in patients with
double-vessel coronary disease (7.36 ± 6.07, N = 28),
triple-vessel disease (10.33 ± 7.78, N = 18), or left main
trunk stenosis (16.17 ± 5.34, N = 6) than in those with
normal coronary arteries, but did not differ between pa-
tients with single-vessel disease (6.39 ± 6.15, N = 41) and
those with normal coronary arteries (Fig. 3).
Diagnostic potential of BMIPP-Tl SPECT
Receiver operating characteristic curves indicated that
ability to diagnose coronary artery disease in hemodialy-
sis patients was higher for BMIPP SPECT than for Tl
SPECT (Fig. 4). When a BMIPP summed score of 6
or more was defined as abnormal, sensitivity, specificity,
positive predictive value, negative predictive value, and
accuracy of detecting coronary artery disese by BMIPP
SPECT were 98.0%, 65.6%, 89.7%, 91.3%, and 90.0%,
respectively. In contrast, these parameters for detect-
ing coronary artery disease by Tl SPECT were 84.7%,
46.9%, 83.0%, 50.0%, and 75.0%, respectively, when a Tl
summed score of 1 or more was defined as abnormal.
Left ventricular function and BMIPP summed score
in the normal coronary group
When a BMIPP summed score of 6 or more was defined
as abnormal, significant differences were recognized be-
tween normal BMIPP (N = 21) and abnormal BMIPP
(N = 11) groups in percent of left ventricular fractional
shortening [37.5 ± 9.2% (N = 21) vs. 30.5 ± 5.7% (N =
11), P < 0.05] and left ventricular ejection fraction [66.2 ±
11.1% (N = 21) vs. 57.6 ± 8.4% (N = 11), P < 0.05]. Age,
gender, presence of diabetes mellitus, serum hemoglobin
A1c concentration, hematocrit, serum concentrations of
hemoglobin, albumin, total cholesterol, cardiothoracic
ratio, blood pressure before or after dialysis, left ventric-
ular dimension, and left ventricular wall thickness did not
differ between the two groups.
Left ventricular wall thickness and BMIPP summed score
No significant correlation was found between interven-
tricular septal wall thickness measured at the left ventric-
ular base and the BMIPP score of the basal anteroseptal
segment (r = 0.069, P = 0.433, N = 130) or between left
ventricular posterior wall thickness measured at the left
ventricular base and the BMIPP score of the basal infer-
olateral segment (r = 0.022, P = 0.802, N = 130).
DISCUSSION
In the present study, coronary artery disease demon-
strated high prevalence of significant coronary artery
stenosis (71.5%) in maintenance hemodialysis patients.
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RCA 1, 90%; 2, 90%;
3, 90%; 4PD, 99%
LAD 7, 75% LCX 13, 100%
BMIPP-SPECT TI-SPECT
Vertical long axis
Short axis
Horizontal long axis
Fig. 1. A hemodialysis patient of 75-year-old
woman showing triple-vessel disease by coro-
nary angiography and differences in imaging
between BMIPP and Tl singlephoton emis-
sion computed tomography (SPECT). Abbre-
viations are: RCA, right coronary artery, PD,
posterior descending branch, LAD, left ante-
rior descending artery; LCX, left circumflex
artery.
A
BMIPP-SPECT TI-SPECT
B
BMIPP-SPECT TI-SPECT
Fig. 2. Two hemodialysis patients showing
significant coronary stenosis by coronary an-
giography and differences in imaging between
BMIPP and Tl single-photon emission com-
puted tomography (SPECT). (A) A 60-year-
old man, 90% stenosis of segment 2 of the
right coronary artery. (B) A 70-year-old man,
90% stenosis of the left main trunk.
Nearly 80% of these patients with coronary artery disease
had no apparent chest pain, independent of the presence
of diabetes mellitus. The mean BMIPP summed score
was higher in hemodialysis patients not only with 90% or
greater but also those with 75% coronary stenosis, than
the scores in those with normal coronary arteries. Fur-
thermore, the mean BMIPP summed score was higher in
patients with single-vessel disease, as well as those with
double- or triple-vessel disease or as left main trunk le-
sion, than in those with normal coronary arteries. When
a BMIPP summed score of 6 or more was defined as ab-
normal, sensitivity, specificity, and accuracy for detecting
coronary artery disease by BMIPP SPECT were 98.0%,
65.6%, and 90.0%, respectively, while these parameters
for detecting coronary artery disease by Tl SPECT were
84.7%, 46.9%, and 75.0% when a Tl summed score of
1 or more was defined as abnormal. Based on receiver
operating characteristic curve analysis, BMIPP SPECT
was superior to Tl SPECT for detecting coronary artery
disease in hemodialysis patients.
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Fig. 3. Relationships of BMIPP and Tl
single-photon emission computed tomogra-
phy (SPECT) to coronary artery disease iden-
tified by coronary angiography (CAG). (A)
BMIPP and Tl SPECT summed scores ac-
cording to degree of coronary artery steno-
sis. (B) BMIPP and Tl SPECT summed scores
according to number of coronary vessels with
significant stenosis (75% or more).
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Fig. 4. Receiver operating characteristic (ROC) curves indicating the
diagnostic potential for coronary artery disease of 123I-BMIPP and 201Tl
single-photon emission computed tomography (SPECT). The area un-
der the curve (AUC) was 0.895 for BMIPP and 0.727 for Tl SPECT,
respectively.
The metabolism and kinetics of BMIPP in myocardial
cells are determined by the following factors: (1) incor-
poration from the blood into cardiac muscle cells via the
CD36-positive FFA binding protein on the myocardial
cell membrane; (2) the back diffusion from within my-
ocardial cells into the blood that occurs immediately af-
ter incorporation (early back diffusion); (3) intracardiac
concentrations of adenosine triphosphate (ATP), which is
required for acylation of BMIPP to acetyl-BMIPP; (4) ac-
cumulation in the lipid pool (about 70%); (5) metabolism
to q-iodophenyl acetic acid via a- or b-oxidation in mi-
tochondria (about 10%); and (6) back diffusion from the
lipid pool into the blood (late back diffusion). Of these
factors, intracardiac ATP and accumulation in the lipid
pool are believed to be significantly associated with early
cardiac imaging findings by BMIPP SPECT [24–30].
Sensitivity of detection of coronary artery stenosis by
BMIPP SPECT has been reported to be higher in un-
stable angina (61% to 74%) [19, 21, 22], than in stable
angina (31.7% to 50.0%) [18, 21]. The overall detection
rate of coronary artery lesions obtained in this study was
higher than those reported in either unstable angina or
stable angina without ESRD. The high detection rate of
coronary artery disease by BMIPP SPECT in hemodial-
ysis patients may be partially explained by structural and
metabolic myocardial abnormalities that are peculiar to
hemodialysis patients.
In experimental models of renal failure and in ure-
mic patients, intramyocardial arteriolar wall thickening
is consistently observed independently of blood pressure
[31, 32]. Thickening of the vascular wall includes distinct
hypertrophy of vascular wall cells as well as a slight in-
crease in the number of cells [33]. Parathyroid hormone
or endothelin may be involved in this arteriolar thick-
ening in hemodialysis patients [34, 35]. In addition, re-
duction of capillary density in the myocardium has been
reported in animal models of renal failure and in ure-
mic patients [31, 36, 37]. Furthermore, an autopsy study
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reported that interstitial fibrosis in the myocardium was
more severe in ESRD patients than in patients with pri-
mary hypertension and diabetes mellitus [37]. Myocar-
dial fibrosis in hemodialysis patients is not substitution
of scar tissue as seen in parenchymal necrosis, but shows
a different pattern resulting from primary activation of
cardiac interstitial fibroblasts. Intramyocardial arteriolar
thickening is likely to interfere with vasodilation. Reduc-
tion of capillary density and myocardial fibrosis increase
intercapillary diffusion distance, decreasing blood and
oxygen supply to cardiomyocytes. All of these myocar-
dial abnormalities in hemodialysis patients render the
myocardium more susceptible to ischemic injury. When
coronary artery stenosis or spasm is present, myocardial
ischemia is thought to be more severe in hemodialysis pa-
tients than in other patients. Myocardial ischemia reduces
the myocardial lipid pool by a shift from lipid to glucose
metabolism, and also decreases myocardial ATP concen-
trations, which would inhibit synthesis of acetyl-BMIPP
and further decrease accumulation of acetyl-BMIPP to
the reduced lipid pool. Therefore, when significant coro-
nary stenosis is present, myocardial accumulation of
123I-BMIPP appears to decrease more sharply in
hemodialysis patients than in nonhemodialysis patients.
A significant drop below 80 mm Hg in mean oxy-
gen tension reportedly occurs during hemodialysis [38,
39]. In addition, blood pressure sometimes reduces to
preshorck levels during hemodialysis, in which inhibited
sympathetic activity or enhanced nitric oxide production
are likely to be involved [40, 41]. Repeated hypoxemia
or hypotension during hemodialysis possibly aggravate
myocardial ischemia in hemodialysis patients with signif-
icant coronary artery stenosis. Although we do not have
direct evidence to prove it, repeated dialysis hypoxemia
or hypotension may have partially contributed to high de-
tection rate of coronary artery disease by BMIPP SPECT
in chronic hemodialysis patients.
Carnitine plays an important role in transport of long-
chain FFA from the cytoplasm to the matrix of my-
ocardial and skeletal muscle mitochondria. Maintenance
hemodialysis patients are in a state of chronic free car-
nitine deficiency, because their diets are limited in foods
containing carnitine, renal synthesis of carnitine is de-
creased, and circulating carnitine is removed during
hemodialysis [42]. Chronic administration of L-carnitine
to hemodialysis patients reportedly did not change ac-
cumulation of 123I-BMIPP in the myocardium or left
ventricular dimension or function, but it increased the
washout rate of 123I-BMIPP [43]. Experimental admin-
istration of etomoxir, a carnitine palmotoyltransferase I
inhibitor, to dogs did not affect retention of 123I-BMIPP
in the heart [32]. Therefore, carnitine deficiency may
have some influence on lipid metabolism in myocardial
cells, but would not seem likely to significantly alter
123I-BMIPP SPECT imaging in maintenance hemodial-
ysis patients.
Circulating FFA increases during hemodialysis, and
plasma FFA concentration is reportedly elevated in ure-
mic patients [44, 45]. Increased circulating FFA may af-
fect the myocardial uptake of BMIPP, because BMIPP
is a branched FFA. In an animal experiment of in-
travenous infusion of triglycerides, the extraction of
123I-BMIPP in canine myocardium decreased, the
washout and backdiffusion increased, but the myocardial
retention level of 123I-BMIPP remained constant [46]. In
a human study, however, myocardial uptake and clear-
ance of 123I-BMIPP had no relation to the levels of blood
triglycerides or FFA, and the detection rate of signifi-
cant coronary artery disease by 123I-BMIPP SPECT did
not differ between the groups of patients with or without
hyperlipidemia [47]. Thus, it seems to be unlikely that
increased circulating FFA affects the detection rate of
coronary artery disease by 123I-BMIPP SPECT in chronic
hemodialysis patients, although we cannot deny the pos-
sibility. Further study is needed to clarify the relationship
between increased circulating FFA and BMIPP SPECT
in chronic hemodialysis patients.
Mismatch between BMIPP and Tl SPECT was ob-
served in hemodialysis patients with coronary artery
disease. This mismatch is usually seen in cases of im-
paired fatty acid metabolism despite restored coronary
perfusion such as stunned myocardium. However, the
mechanism causing BMIPP-Tl mismatch in chronic
hemodialysis patients with coronary artery disease may
be different from that of stunned myocardium. In a study
which assessed the relationship between 123I-BMIPP up-
take and myocardial fibrosis in chronic hypoperfused
human heart, Kudoh et al [48] disclosed that BMIPP-
Tl mismatch was found only in ischemic myocardium in
which the extent of fibrotic changes was less than 20%.
Interstitial fibrosis in the myocardium is generally recog-
nized in ESRD patients [37], as described above. Myocar-
dial fibrotic changes in chronic hemodialysis patients with
coronary artery disease are not likely to be severe because
left ventricular function was relatively reserved. BMIPP-
Tl mismatch in chronic hemodialysis patients without
acute myocardial ischemia may indicate changes in fatty
acid metabolism of the ischemic myocardium that has
mild interstitial fibrosis.
Specificity of BMIPP SPECT for diagnosis of coronary
artery disease in hemodialysis patients (65.6%) was con-
siderably lower than sensitivity, and also was lower than
specificity in nonhemodialysis patients (80% to 93.8%)
according to the previous reports [18, 21]. In the nor-
mal coronary artery group, almost one third of patients
showed a high BMIPP score of 6 or more. Left ventric-
ular fractional shortening and ejection fraction, which
are parameters of left ventricular systolic function and
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depend largely on myocardial ATP, were less in patients
with a higher BMIPP summed score than in those with a
lower BMIPP summed score within the normal coronary
group. This finding may reflect abnormalities of myocar-
dial microcirculation induced by the structural changes,
which are likely to be greater in patients with a higher
BMIPP summed score. Further investigation is needed
to clarify the mechanism of reduced uptake of BMIPP in
hemodialysis patients with normal coronary arteries.
Results of the present study showed that prevalence
of silent myocardial ischemia is unexpectedly high in
chronic hemodialysis patients. We aimed to exclude the
patients with apparent history or echocardiographic find-
ings showing the presence of old myocardial infarction
from the subjects. However, as a study limitation, we
may have not been able to completely exclude the pa-
tients with a small and mild old myocardial infarction
induced by silent myocardial ischemia from the study
because electrocardiographic abnormalities often are
difficult to interpret in hemodialysis patients and echocar-
diographic findings are sometimes within normal range in
a revascularized small old myocardial infarction.
Because all subjects of the present study were outpa-
tients who had been going to hospital regularly, only early
image BMIPP and Tl dual SPECT was carried out in the
present study. Results of the present study indicate that an
early image of BMIPP SPECT is enough for screening of
coronary artery disease without spending time. However,
it would be meaningful to evaluate the diagnostic value of
delayed image as well as early image of BMIPP SPECT
for detecting coronary artery disease in hemodialysis pa-
tients, because addition of delayed image may improve
the diagnostic potential of BMIPP SPECT.
CONCLUSION
Results obtained in this study indicate greater use-
fulness for resting 123I-BMIPP SPECT in detection of
coronary artery disease in chronic hemodialysis patients
than for 201Tl SPECT. The high sensitivity and accuracy
in detecting coronary artery stenosis demonstrated that
resting 123I-BMIPP SPECT appears adequate for screen-
ing for coronary artery disease in hemodialysis patients.
The number of ESRD patients undergoing maintenance
hemodialysis is increasing every year, with the most com-
mon underlying disease being diabetes mellitus, where
atherosclerosis/arteriosclerosis generally occurs systemi-
cally including coronary artery involvement. To decrease
risk of future cardiac events such as acute myocardial
infarction or congestive heart failure caused by myocar-
dial ischemia in chronic hemodialysis patients, asymp-
tomatic coronary artery disease should be diagnosed as
soon as possible, ultimately by coronary angiography, and
then treated by percutaneous coronary intervention or
coronary artery bypass grafting. We believe that resting
123I-BMIPP SPECT provides sufficient information to
determine whether a maintenance hemodialysis patient
with no apparent chest pain should undergo coronary
angiography.
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